Neuraminidase inhibitors for treatment of influenza A and B infections.
Identifieur interne : 001974 ( Main/Exploration ); précédent : 001973; suivant : 001975Neuraminidase inhibitors for treatment of influenza A and B infections.
Auteurs :Source :
- MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports [ 1057-5987 ] ; 1999.
Descripteurs français
- KwdFr :
- Acides sialiques (administration et posologie), Acides sialiques (effets indésirables), Acides sialiques (pharmacocinétique), Acides sialiques (usage thérapeutique), Acétamides (administration et posologie), Acétamides (effets indésirables), Acétamides (pharmacocinétique), Acétamides (usage thérapeutique), Adolescent, Adulte, Antienzymes (administration et posologie), Antienzymes (effets indésirables), Antienzymes (pharmacocinétique), Antienzymes (usage thérapeutique), Antiviraux (administration et posologie), Antiviraux (effets indésirables), Antiviraux (pharmacocinétique), Antiviraux (usage thérapeutique), Grippe humaine (traitement médicamenteux), Guanidines, Humains, Interactions médicamenteuses, Oséltamivir, Pyrannes, Résistance microbienne aux médicaments, Sialidase (antagonistes et inhibiteurs), Virus de la grippe A, Virus influenza B, Zanamivir.
- MESH :
- administration et posologie : Acides sialiques, Acétamides, Antienzymes, Antiviraux.
- antagonistes et inhibiteurs : Sialidase.
- effets indésirables : Acides sialiques, Acétamides, Antienzymes, Antiviraux.
- pharmacocinétique : Acides sialiques, Acétamides, Antienzymes, Antiviraux.
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Acides sialiques, Acétamides, Antienzymes, Antiviraux.
- Adolescent, Adulte, Guanidines, Humains, Interactions médicamenteuses, Oséltamivir, Pyrannes, Résistance microbienne aux médicaments, Virus de la grippe A, Virus influenza B, Zanamivir.
English descriptors
- KwdEn :
- Acetamides (administration & dosage), Acetamides (adverse effects), Acetamides (pharmacokinetics), Acetamides (therapeutic use), Adolescent, Adult, Antiviral Agents (administration & dosage), Antiviral Agents (adverse effects), Antiviral Agents (pharmacokinetics), Antiviral Agents (therapeutic use), Drug Interactions, Drug Resistance, Microbial, Enzyme Inhibitors (administration & dosage), Enzyme Inhibitors (adverse effects), Enzyme Inhibitors (pharmacokinetics), Enzyme Inhibitors (therapeutic use), Guanidines, Humans, Influenza A virus, Influenza B virus, Influenza, Human (drug therapy), Neuraminidase (antagonists & inhibitors), Oseltamivir, Pyrans, Sialic Acids (administration & dosage), Sialic Acids (adverse effects), Sialic Acids (pharmacokinetics), Sialic Acids (therapeutic use), Zanamivir.
- MESH :
- chemical , administration & dosage : Acetamides, Antiviral Agents, Enzyme Inhibitors, Sialic Acids.
- chemical , adverse effects : Acetamides, Antiviral Agents, Enzyme Inhibitors, Sialic Acids.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , pharmacokinetics : Acetamides, Antiviral Agents, Enzyme Inhibitors, Sialic Acids.
- chemical , therapeutic use : Acetamides, Antiviral Agents, Enzyme Inhibitors, Sialic Acids.
- drug therapy : Influenza, Human.
- Adolescent, Adult, Drug Interactions, Drug Resistance, Microbial, Guanidines, Humans, Influenza A virus, Influenza B virus, Oseltamivir, Pyrans, Zanamivir.
Abstract
Influenza epidemics are responsible for an average of approximately 20,000 deaths per year in the United States. The main method for preventing influenza and its severe complications is influenza vaccination. Influenza-specific antiviral drugs are an important adjunct to vaccine but are not a substitute for vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine was approved for prophylaxis of influenza A(H2N2) infection in the United States in 1966 and was approved for prophylaxis and treatment of influenza A infection in 1976; rimantadine was approved for treatment and prophylaxis of influenza A infection in 1993 [corrected]. This report provides information on two neuraminidase inhibitors, zanamivir and oseltamivir, which were approved in 1999. Neuraminidase inhibitors are a new class of antiviral drugs that inhibit influenza A and B viruses. Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in persons aged > or =12 years who have been symptomatic for no more than 2 days. Oseltamivir is approved for treatment of uncomplicated illness caused by influenza infection in adults aged > or =18 years who have been symptomatic for no more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza prophylaxis. This report and the Advisory Committee on Immunization Practices (ACIP) 1999 recommendations on influenza prevention and control (MMWR 1999;48[No.RR-4]:1-28) can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at or at the MMWR website at .
PubMed: 10632443
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000369
- to stream PubMed, to step Curation: 000369
- to stream PubMed, to step Checkpoint: 000338
- to stream Ncbi, to step Merge: 000015
- to stream Ncbi, to step Curation: 000015
- to stream Ncbi, to step Checkpoint: 000015
- to stream Main, to step Merge: 001A19
- to stream Main, to step Curation: 001974
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neuraminidase inhibitors for treatment of influenza A and B infections.</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10632443</idno>
<idno type="pmid">10632443</idno>
<idno type="wicri:Area/PubMed/Corpus">000369</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000369</idno>
<idno type="wicri:Area/PubMed/Curation">000369</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000369</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000338</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000338</idno>
<idno type="wicri:Area/Ncbi/Merge">000015</idno>
<idno type="wicri:Area/Ncbi/Curation">000015</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000015</idno>
<idno type="wicri:Area/Main/Merge">001A19</idno>
<idno type="wicri:Area/Main/Curation">001974</idno>
<idno type="wicri:Area/Main/Exploration">001974</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neuraminidase inhibitors for treatment of influenza A and B infections.</title>
</analytic>
<series><title level="j">MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports</title>
<idno type="ISSN">1057-5987</idno>
<imprint><date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acetamides (administration & dosage)</term>
<term>Acetamides (adverse effects)</term>
<term>Acetamides (pharmacokinetics)</term>
<term>Acetamides (therapeutic use)</term>
<term>Adolescent</term>
<term>Adult</term>
<term>Antiviral Agents (administration & dosage)</term>
<term>Antiviral Agents (adverse effects)</term>
<term>Antiviral Agents (pharmacokinetics)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Drug Interactions</term>
<term>Drug Resistance, Microbial</term>
<term>Enzyme Inhibitors (administration & dosage)</term>
<term>Enzyme Inhibitors (adverse effects)</term>
<term>Enzyme Inhibitors (pharmacokinetics)</term>
<term>Enzyme Inhibitors (therapeutic use)</term>
<term>Guanidines</term>
<term>Humans</term>
<term>Influenza A virus</term>
<term>Influenza B virus</term>
<term>Influenza, Human (drug therapy)</term>
<term>Neuraminidase (antagonists & inhibitors)</term>
<term>Oseltamivir</term>
<term>Pyrans</term>
<term>Sialic Acids (administration & dosage)</term>
<term>Sialic Acids (adverse effects)</term>
<term>Sialic Acids (pharmacokinetics)</term>
<term>Sialic Acids (therapeutic use)</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Acides sialiques (administration et posologie)</term>
<term>Acides sialiques (effets indésirables)</term>
<term>Acides sialiques (pharmacocinétique)</term>
<term>Acides sialiques (usage thérapeutique)</term>
<term>Acétamides (administration et posologie)</term>
<term>Acétamides (effets indésirables)</term>
<term>Acétamides (pharmacocinétique)</term>
<term>Acétamides (usage thérapeutique)</term>
<term>Adolescent</term>
<term>Adulte</term>
<term>Antienzymes (administration et posologie)</term>
<term>Antienzymes (effets indésirables)</term>
<term>Antienzymes (pharmacocinétique)</term>
<term>Antienzymes (usage thérapeutique)</term>
<term>Antiviraux (administration et posologie)</term>
<term>Antiviraux (effets indésirables)</term>
<term>Antiviraux (pharmacocinétique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Grippe humaine (traitement médicamenteux)</term>
<term>Guanidines</term>
<term>Humains</term>
<term>Interactions médicamenteuses</term>
<term>Oséltamivir</term>
<term>Pyrannes</term>
<term>Résistance microbienne aux médicaments</term>
<term>Sialidase (antagonistes et inhibiteurs)</term>
<term>Virus de la grippe A</term>
<term>Virus influenza B</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Sialic Acids</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Sialic Acids</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Sialic Acids</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Acetamides</term>
<term>Antiviral Agents</term>
<term>Enzyme Inhibitors</term>
<term>Sialic Acids</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Acides sialiques</term>
<term>Acétamides</term>
<term>Antienzymes</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Acides sialiques</term>
<term>Acétamides</term>
<term>Antienzymes</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacocinétique" xml:lang="fr"><term>Acides sialiques</term>
<term>Acétamides</term>
<term>Antienzymes</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Acides sialiques</term>
<term>Acétamides</term>
<term>Antienzymes</term>
<term>Antiviraux</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Drug Interactions</term>
<term>Drug Resistance, Microbial</term>
<term>Guanidines</term>
<term>Humans</term>
<term>Influenza A virus</term>
<term>Influenza B virus</term>
<term>Oseltamivir</term>
<term>Pyrans</term>
<term>Zanamivir</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Guanidines</term>
<term>Humains</term>
<term>Interactions médicamenteuses</term>
<term>Oséltamivir</term>
<term>Pyrannes</term>
<term>Résistance microbienne aux médicaments</term>
<term>Virus de la grippe A</term>
<term>Virus influenza B</term>
<term>Zanamivir</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza epidemics are responsible for an average of approximately 20,000 deaths per year in the United States. The main method for preventing influenza and its severe complications is influenza vaccination. Influenza-specific antiviral drugs are an important adjunct to vaccine but are not a substitute for vaccine. In the United States, four antiviral agents are approved for preventing or treating influenza: amantadine, rimantadine, zanamivir, and oseltamivir. Amantadine was approved for prophylaxis of influenza A(H2N2) infection in the United States in 1966 and was approved for prophylaxis and treatment of influenza A infection in 1976; rimantadine was approved for treatment and prophylaxis of influenza A infection in 1993 [corrected]. This report provides information on two neuraminidase inhibitors, zanamivir and oseltamivir, which were approved in 1999. Neuraminidase inhibitors are a new class of antiviral drugs that inhibit influenza A and B viruses. Zanamivir is approved for treatment of uncomplicated acute illness caused by influenza virus in persons aged > or =12 years who have been symptomatic for no more than 2 days. Oseltamivir is approved for treatment of uncomplicated illness caused by influenza infection in adults aged > or =18 years who have been symptomatic for no more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza prophylaxis. This report and the Advisory Committee on Immunization Practices (ACIP) 1999 recommendations on influenza prevention and control (MMWR 1999;48[No.RR-4]:1-28) can be accessed at the website for the Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC, at or at the MMWR website at .</div>
</front>
</TEI>
<affiliations><list></list>
<tree></tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001974 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001974 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= H2N2V1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:10632443 |texte= Neuraminidase inhibitors for treatment of influenza A and B infections. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:10632443" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a H2N2V1
This area was generated with Dilib version V0.6.33. |